A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions

• Status: Completed
• Trial end date: 2017-11-20
• Target enrollment: 0
• Participant gender: Female

Summary

This is a safety and efficacy study of LiRIS® in females with interstitial cystitis with Hunner's lesions.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Lidocaine

Criteria

Inclusion Criteria:

• Diagnosis of interstitial cystitis with Hunner's lesions/ulcers

Exclusion Criteria:

• Previous treatment with LiRIS®

• Interstitial cystitis/bladder pain syndrome, without Hunner's lesions/ulcers